Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Total Liabilities
Everything the company owes to creditors and other parties.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 34.9% from a year ago
Total liabilities stood at $34.06M at the end of Q1 FY2026, down 34.9% from a year earlier and down 2.7% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.
Context
- Total liabilities amounted to 47.5% of total assets at the end of Q1 FY2026, down 65.1 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -34.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 35.02M USD
- Year-over-year change
- -31.1%
- 4-year CAGR
- +51.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.02M | -31.1% |
| FY2024 | 2024-12-31 | 50.82M | +32.0% |
| FY2023 | 2023-12-31 | 38.49M | +30.4% |
| FY2022 | 2022-12-31 | 29.51M | +344.3% |
| FY2021 | 2021-12-31 | 6.64M | — |
Total Liabilities vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -34.9% is the lowest of 8, against a peer median of +5.2%.
- Total liabilities amounts to 47.5% of total assets for FRX.TO, versus a peer median of 31.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $458.48M USD | +5.2% | -3.2% | 83.4% | |
| Mar 2026 | CA$421.14M CAD | -2.2% | -36.9% | 37.6% | |
| Mar 2026 | $160.55M USD | -15.1% | -13.2% | 57.7% | |
| Mar 2026 | CA$149.5M CAD | +1.5% | — | 28.7% | |
| Mar 2026 | $34.06M USD | -34.9% | +5.9% | 47.5% | |
PRN.TOProfound Medical Corp. | Mar 2026 | $14.04M USD | +39.4% | +81.5% | 19.1% |
| Mar 2026 | $9.17M USD | +316.9% | -26.8% | 6.3% | |
| Apr 2026 | CA$6.69M CAD | +179.0% | -1.9% | 31.3% | |
| Peer median (excluding FRX.TO) | — | +5.2% | -8.2% | 31.3% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.1M | 23.77M | 13.27M | 26.63M | 36.72M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 1.55M | 8.81M | 12.88M | 23.18M |
| Inventory | 0 | 576K | 2.16M | 1.06M | 1.56M |
| Other Current Assets | 253K | 63K | 44K | 466K | 1.37M |
| Total Current Assets | 22.39M | 26.73M | 26.86M | 44.12M | 66.56M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.79M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 27K | 211K | 6K | 822K | 710.62K |
| Total Non-current Assets | 27K | 211K | 6K | 822K | 3.5M |
| Total Assets | 22.41M | 26.94M | 26.86M | 44.95M | 70.07M |
| Account Payables | 777K | 2.39M | 3.78M | 3.24M | 4.63M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 248K | 247.55K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | (10.25K) |
| Total Current Liabilities | 1.65M | 4.61M | 7.55M | 6.92M | 10.5M |
| Long-term Debt | 4.99M | 24.9M | 30.93M | 19.34M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 24.56M |
| Other Non-current Liabilities | 0 | 0 | 0 | 24.56M | 0 |
| Total Non-current Liabilities | 4.99M | 24.9M | 30.93M | 43.9M | 24.52M |
| Total Liabilities | 6.64M | 29.51M | 38.49M | 50.82M | 35.02M |
| Common Stock | 140.8M | 142.59M | 144.31M | 145.61M | 189.56M |
| Retained Earnings | (179.49M) | (203.2M) | (219.25M) | (219.68M) | (229.36M) |
| Accumulated OCI | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.77M | (2.57M) | (11.62M) | (5.87M) | 35.05M |
| Total Debt | 4.99M | 24.9M | 30.95M | 19.34M | 0 |
| Net Debt | (16.11M) | 1.13M | 17.69M | (7.29M) | (36.72M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.